A new urine test kit could transform the fight against malaria
In the last 18 months, Africa’s healthcare system and issues have come under the spotlight due the world’s worst Ebola outbreak. According to the World Health Organization, the virus has led to the deaths of around 11,000 people but Africa has an even more rampant disease with which it continues to contend: malaria.
Malaria infects some 300 million to 600 million every year around the world, according to Unicef. But Sub-Saharan Africa alone accounts for90% of the world’s 580,000 annual malaria deaths and Nigeria accounts for 18% of global infections.
However, it appears the fight against malaria in Nigeria is set for a huge boost as the world’s first urine malaria test is set to debut. Created byFyodor, a US based biotechnology firm founded by Nigerian Eddy Agbo, the urine malaria test provides point-of-need diagnosis of the Plasmodium parasite using dipstick technology as used with manual pregnancy tests. The urine malaria test is expected to be in pharmacies across Nigeria before the end of the year.
The do-it-yourself solution delivers a diagnosis within 20 minutes of testing and can be done by people with little or no training.
How the Urine Malaria test works. (courtesy Fyodor)
The potential of offering accurate and early diagnosis of the malaria parasite can speed up the process of tackling malaria in rural areas lacking in healthcare infrastructure and also reduces the risk of the wrong treatment. Tracking the accurate death toll of malaria in Nigeria is not an exact science as a significant number of deaths may go unreported.
The Urine Malaria Test won the inaugural 2015 Health Innovation Challenge Awards in Nigeria this month, backed by the Private Sector Health Alliance of Nigeria (PHN). The award comes with a grant of $100,000 and support for PHN from backers including Bill Gates; Africa’s wealthiest man, Aliko Dangote; and former Nigerian president Goodluck Jonathan.
Asides from fatalities, malaria also has a devastating effect on productivity in Sub-Saharan Africa. The disease costs the region up to$12 billion in trade, foreign investment and tourism.
This article is published in collaboration with Quartz Africa. Publication does not imply endorsement of views by the World Economic Forum.
To keep up with the Agenda subscribe to our weekly newsletter.
Author: Yomi Kazeem is a writer at Quartz Africa.
Image: Test tubes filled with samples. REUTERS/Suzanne Plunkett.
Don't miss any update on this topic
Create a free account and access your personalized content collection with our latest publications and analyses.
License and Republishing
World Economic Forum articles may be republished in accordance with the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International Public License, and in accordance with our Terms of Use.
The views expressed in this article are those of the author alone and not the World Economic Forum.
Stay up to date:
Future of Global Health and Healthcare
Related topics:
The Agenda Weekly
A weekly update of the most important issues driving the global agenda
You can unsubscribe at any time using the link in our emails. For more details, review our privacy policy.
More on Emerging TechnologiesSee all
Filipe Beato and Jamie Saunders
November 21, 2024